Physician profile
Leon R Robison
NPI 1265547038
$1,164.47
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,040 · 2020: $89.94 · 2024: $34.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $34.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $34.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $381.57 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $224.11 | 2019-2024 | Delstrigo, Pifeltro |
| Janssen Biotech, INC. | $141.68 | 2019-2020 | |
| Gilead Sciences, INC. | $56.77 | 2019 | |
| Mylan Institutional INC. | $43.25 | 2019 | |
| Pfizer INC. | $34.32 | 2019 | |
| Amgen INC. | $32.07 | 2019 | |
| Paratek Pharmaceuticals, INC. | $30.18 | 2019 | |
| Sanofi Pasteur INC. | $28.02 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.77 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $23.91 | 2019 | |
| Ucb, INC. | $20.65 | 2019 | |
| Fresenius USA Marketing, INC. | $17.19 | 2019 | |
| Horizon Therapeutics Plc | $16.62 | 2019 | |
| Genzyme Corporation | $16.06 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16.02 | 2019 | |
| Daiichi Sankyo INC. | $15.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.51 | 2020 | |
| Opko Pharmaceuticals, LLC | $14.41 | 2020 | |
| Allergan, INC. | $12.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.